作者
Augusto Vaglio, Alessandra Palmisano, Federico Alberici, Umberto Maggiore, Stefania Ferretti, Rocco Cobelli, Francesco Ferrozzi, Domenico Corradi, Carlo Salvarani, Carlo Buzio
发表日期
2011/7/23
期刊
The Lancet
卷号
378
期号
9788
页码范围
338-346
出版商
Elsevier
简介
Background
Glucocorticoids are the mainstay of treatment of idiopathic retroperitoneal fibrosis, but they often have substantial toxic effects. Several reports have suggested tamoxifen as an alternative to glucocorticoids. We compared the efficacy of prednisone with that of tamoxifen in maintainance of remission in patients with idiopathic retroperitoneal fibrosis.
Methods
In this open-label, randomised controlled trial, we enrolled patients aged 18–85 years with newly diagnosed idiopathic retroperitoneal fibrosis at the Parma Hospital, Parma, Italy, between Oct 1, 2000, and June 30, 2006. After induction therapy with 1 mg/kg daily of prednisone for 1 month, the patients who achieved remission were randomly assigned to receive tapering prednisone (initial dose 0·5 mg/kg daily) for 8 months or tamoxifen (fixed dose 0·5 mg/kg daily) for 8 months. The sequence of randomisation (1:1), blocked in groups of two and four (with …
引用总数
2011201220132014201520162017201820192020202120222023202441231242328211626191815245